ERS International Congress, Milan 2017

---

The spectrum of CTDs: from pathogenesis to treatment

Thematic Poster
Chairs: M. Bonifazi (Ancona, AN, Italy), J. Wälscher (Heidelberg, Germany), A. Tzouvelekis (Athens, Greece), D. Bouros (Athens, Greece)

Late Breaking Abstract - ND-L02-s0201 treatment leads to efficacy in preclinical IPF models S. Zabludoff (San Diego, United States of America)
Comorbid interstitial lung diseases and collagen vascular diseases in pulmonary alveolar proteinosis: a nationwide surveillance in Japan Y. Inoue (Osaka, Japan)
Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease (CTD-ILD):a cross-sectional study and longitudinal study G. ZIJUN (Guangzhou, China)
Anti-synthetase syndrome associated Interstitial Lung Disease (ASS-ILD): Clinical, serological and radiological heterogeneity A. Rathnapala (Minuwangoda, Sri Lanka)
Anti-synthetase syndrome associated Interstitial Lung Disease (ASS-ILD): clinical heterogeneity and outcome A. Rathnapala (Minuwangoda, Sri Lanka)
DIFFUSING CAPACITY (DLCO) AS A POTENTIAL SURROGATE MARKER FOR SCLERODERMA RELATED LUNG DISEASE– DATA FROM THE GERMAN NETWORK FOR SYSTEMIC SCLEROSIS M. Kreuter (Heidelberg, Germany)
Male gender and fibrosis score on high-resolution computed tomography are independent poor prognostic factors of survival in patients with rheumatoid arthritis-related interstitial lung disease. Y. Ito (Kurashiki, Japan)
Mortality and clinical features in rheumatoid arthritis and interstitial lung disease M. Nieto Barbero (Madrid, Spain)
Clinical Features and Prognosis of Acute exacerbation of Connective Tissue Diseases Associated Pulmonary Fibrosis------ Comparision with Idiopathic Pulmonary Fibrosis M. Cao (Nanjing, China)
Extensive interstitial lung disease in inflammatory myopathy is a strong predictor of mortality D. Assayag (Montréal, QC, Canada)
Management of ANCA-associated vasculitis (AAV): A single-centre perspective from respiratory clinic. T. Nagarajan (Cheshire, United Kingdom)
Risk factors for lung involvements in patients with Sjögren's syndrome T. Kakugawa (Nagasaki, Japan)
Rituximab improves interstitial lung disease in rheumatoid arthritis patients M. Nieto Barbero (Madrid, Spain)
Cardiovascular comorbidity in Danish patients with scleroderma-associated interstitial lung disease G. Madsen (Aarhus, Denmark)
The basic helix-loop-helix transcription factor scleraxis (Scx) is overexpressed in systemic and lung fibrosing diseases C. Mendoza-Milla (MEXICO, Mexico)
Idiopathic and secondary usual interstitial pneumonia: is there a real difference? M. Pinto Mendes (Penafiel, Portugal)
Inmunosuppresor therapy effectivness in Interstitial Lung Disease (ILD) associated Connective Tisuue Disease(CTD). M. Alonso (Montevideo, Uruguay)
Rituximab in the management of idiopathic inflammatory myopathies complicated by interstitial lung disease P. Riddell (Dublin, Ireland)
Autoantibodies in interstitial lung disease A. Jee (Sydney, NSW, Australia)
Serum anti DFS70 antibody titer and lung functional impairment in patients with interstitial lung disease (ILD) F. Bonella (Dusseldorf, Germany)